Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Nevro Corp.
Exec Chat: Abbott’s Burton Talks About Abbott’s Plans To Address Chronic Pain With SCS
Allen Burton, the medical director of Abbott’s neuromodulation business and a leader in pain medicine, talked to Medtech Insight about the FDA’s new labeling for Abbott’s spinal cord stimulation devices that includes non-surgical back pain.
Nevro Names Kevin Thornal As Its New CEO; Investors Remain Disappointed In Results
Thornal will replace Keith Grossman who is retiring. Investors and analysts hope Thornal will help the spinal cord stimulation company reach profitability by growing its “core” chronic pain business.
Nevro Attacks Pain And Competition With Individualized AI-Enabled Spinal Cord Stimulator
The company is selling the Senza HFX iQ spinal cord stimulation system across the US following a successful limited market release.
Minute Insight: Abbott Receives US FDA Clearance For Spinal Cord Stimulator
Abbott announced on 19 December that the US Food and Drug Administration has approved its Eterna spinal cord stimulation system (SCS) for treating chronic pain with low-dose BURSTDR stimulation.
Company Information
- Industry
-
Medical Devices
- Implantable Devices
- Other Names / Subsidiaries
-
- Nevro Medical Limited
- Nevro Medical Pty Ltd.
- Nevro Medical Sarl
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice